BRAF and cancer: Considering recent evidence suggesting that PTEN mutation results in resistance to EGFR-targeted therapies (Sartore-Bianchi et al, 2009), the inhibition of TOPK in KRAS and BRAF wild-type patients could represent an approach to improve clinical outcome in patients with either PTEN wild-type or mutated cancers.